Results 181 to 190 of about 11,039 (220)
Multidisciplinary Management of Acute Tetraparesis in an Infant with Achondroplasia, with a Focus on Anesthetic Strategies: A Case Report. [PDF]
Nedomová B +5 more
europepmc +1 more source
Health-Related Quality of Life of Individuals with Physical Disabilities in Childhood. [PDF]
Church C +10 more
europepmc +1 more source
Mutations in FGFR3 gene in Croatian patients with achondroplasia and hypochondroplasia
Ivona Sansović +2 more
openalex +1 more source
Mental health conditions, physical functioning, and health-related quality of life in adults with a skeletal dysplasia: a cross-sectional multinational study. [PDF]
Fagereng E +10 more
europepmc +1 more source
Spatiotemporal Regulation and Lineage Specification in Embryonic Endochondral Ossification. [PDF]
Wu S, Kondo K, Matsushita Y.
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Best Practice & Research Clinical Rheumatology, 2008
Achondroplasia (MIM 100800) is the most common non-lethal skeletal dysplasia. Its incidence is between one in 10,000 and one in 30,000. The phenotype is characterized by rhizomelic disproportionate short stature, enlarged head, midface hypoplasia, short hands and lordotic lumbar spine, associated with normal cognitive development.
Geneviève, Baujat +4 more
+6 more sources
Achondroplasia (MIM 100800) is the most common non-lethal skeletal dysplasia. Its incidence is between one in 10,000 and one in 30,000. The phenotype is characterized by rhizomelic disproportionate short stature, enlarged head, midface hypoplasia, short hands and lordotic lumbar spine, associated with normal cognitive development.
Geneviève, Baujat +4 more
+6 more sources
Advances in Therapy, 2023
Introduction Vosoritide is the first precision medical therapy approved to increase growth velocity in children with achondroplasia. Sharing early prescribing experiences across different regions could provide a framework for developing practical ...
Oliver Semler +19 more
semanticscholar +1 more source
Introduction Vosoritide is the first precision medical therapy approved to increase growth velocity in children with achondroplasia. Sharing early prescribing experiences across different regions could provide a framework for developing practical ...
Oliver Semler +19 more
semanticscholar +1 more source

